Medscape Medical NewsAll articles

Vital Signs

Oxehealth Limited • Cardiovascular • 07/20/2021

510(k)IEC 62304 Class C
FDA Summary PDF

Device Purpose

Oxehealth Vital Signs is a software-based system that utilizes fixed optical sensors and proprietary algorithms to noninvasively measure pulse rate via remote photoplethysmography and estimate breathing rate from chest wall movements in video. It is designed for spot-check monitoring of still, adult subjects in non-critical care settings by trained healthcare professionals, with performance validated against clinical reference standards.

Summary

Oxehealth Vital Signs is a software-based medical device designed for noninvasive spot measurement of pulse rate and estimated breathing rate. It operates by analyzing video footage captured by a fixed-installation optical sensor (camera) located in a single occupancy room. The system utilizes proprietary algorithms: pulse rate is determined by detecting subtle skin color changes indicative of blood flow (remote photoplethysmography - rPPG), while breathing rate is estimated from subtle chest wall movements visible in the video. The device is intended for use by trained healthcare professionals to monitor adult patients (18 years or older) who are still and do not require critical care or continuous vital signs monitoring. It is designed for environments such as hospitals, general care facilities, and secured settings where periodic health checks are standard practice. The underlying science involves optical sensing and algorithmic interpretation of physiological signals from video. Pulse rate measurement relies on rPPG technology, while breathing rate estimation is based on motion analysis of the chest. The system's performance has been validated through non-clinical software verification and validation, including algorithm performance, usability, and cybersecurity assessments. Clinical validation studies compared its accuracy for pulse rate and breathing rate against recognized reference methods (like pulse oximeters, ECG, manual counts, or capnography) in diverse adult populations within intended use environments, meeting predefined acceptance criteria. It's important to note that this device is not intended to be the sole method for assessing a subject's physical health and is specifically for non-continuous, spot-check measurements when the subject is still.

AI Regulatory Concerns

Powered byJev by TypeSafe AI

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

Keywords

Optical sensingVital signs monitoringPulse rateBreathing rateRemote photoplethysmography (rPPG)Video analysisSoftware as a Medical Device (SaMD)Noninvasive measurementChest wall movementSpot-check monitoring

Device Metadata

Submission Number
K211906
Company
Oxehealth Limited
Panel
Cardiovascular
Product Code
N/A
Data Type
Images
Clinical Function
Assessment
AI Function
Analysis
AI Subclass
quantification/feature localization

Relevant Clinical Questions

  • Q1. What is the validated range of skin tones and lighting conditions under which the rPPG algorithm maintains its stated accuracy for pulse rate measurement?; How does the system differentiate between actual chest wall movements for breathing rate and other body movements, especially in restless but not critically ill subjects?; What are the specific performance metrics (e.g., mean absolute error, limits of agreement) from the clinical validation studies when compared to the reference methods for both pulse rate and breathing rate?; Could the video footage be retrospectively analyzed for other subtle physiological or behavioral markers beyond pulse and breathing rate, and what ethical considerations would this entail?; What is the minimum duration of "stillness" required by the subject for the device to acquire accurate pulse rate and breathing rate measurements?

Risk Classification

ESL Analysis
FDA Device ClassII

FDA Class II via 510(k) pathway; IEC 62304 Class C (software safety classification); Authorized before §524B enforcement

Learn how Parasoft automates IEC 62304 compliance testing →

Cybersecurity Evidence

Powered by SBOMator™

Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.

Cyber Score55/100
SBOM Evidence⚠ Not mentioned in summary
Cyber Risk Assessment✓ Detected in Summary
Postmarket Plan✓ Detected in Summary
§524B ApplicableNo

Supply Chain BOM Evidence

Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.

SBOMSoftware Bill of Materials
- Not detected
ML-BOMMachine Learning Bill of Materials(algorithm)
✓ Detected
SaaSBOMSoftware-as-a-Service Bill of Materials(remote)
✓ Detected
HBOMHardware Bill of Materials(sensor, camera)
✓ Detected
CBOMCryptography Bill of Materials
- Not detected
VDR/VEXVulnerability Disclosure Report / Vulnerability Exploitability eXchange
- Not detected
OBOMOperations Bill of Materials(environment)
✓ Detected

Analysis:

• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.

• Evidence of ML-BOM, SaaSBOM, HBOM, OBOM detected in AI-generated device summary.

• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.

• Not detected in AI-generated device summary: SBOM, CBOM, VDR/VEX. These may be present in the full FDA submission.

Preparing a similar submission?

ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.

Assess Your Readiness →Or contact ESL directly
Vital Signs - Oxehealth Limited | ESL FDA AI Device Intelligence